Ellis Levine

5.6k total citations · 1 hit paper
92 papers, 2.8k citations indexed

About

Ellis Levine is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Ellis Levine has authored 92 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 40 papers in Pulmonary and Respiratory Medicine and 25 papers in Cancer Research. Recurrent topics in Ellis Levine's work include Breast Cancer Treatment Studies (18 papers), Advanced Breast Cancer Therapies (14 papers) and Prostate Cancer Treatment and Research (14 papers). Ellis Levine is often cited by papers focused on Breast Cancer Treatment Studies (18 papers), Advanced Breast Cancer Therapies (14 papers) and Prostate Cancer Treatment and Research (14 papers). Ellis Levine collaborates with scholars based in United States, Canada and France. Ellis Levine's co-authors include C. D. Bloomfield, Nicholas J. Vogelzang, Susan Halabi, Ellen B. Kaplan, Philip W. Kantoff, Eric J. Small, Nancy A. Dawson, Brent A. Blumenstein, Michael W. Kattan and Stephen B. Edge and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ellis Levine

86 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer

2003 541 citations Ellis Levine, Nicholas J. Vogelzang et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Ellis Levine

Since Specialization

Citations

This map shows the geographic impact of Ellis Levine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellis Levine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellis Levine more than expected).

Fields of papers citing papers by Ellis Levine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellis Levine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellis Levine. The network helps show where Ellis Levine may publish in the future.

Co-authorship network of co-authors of Ellis Levine

This figure shows the co-authorship network connecting the top 25 collaborators of Ellis Levine. A scholar is included among the top collaborators of Ellis Levine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellis Levine. Ellis Levine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer 2025 ·Oncogene ·Agnieszka K. Witkiewicz, (unknown), Emily Schultz, (unknown), Tracey L. O’Connor, Ellis Levine, Erik S. Knudsen	0
2	Abstract PO1-18-03: Chemokine-modulating regimen (rintatolimod, IFN-α2b, celecoxib): New strategy to drive CD8+T-cells into triple negative breast cancer 2024 ·Cancer Research ·Shipra Gandhi, (unknown), Mateusz Opyrchal, (unknown), Kristopher Attwood, Jianmin Wang, Eduardo Cortes Gomez, Tracey L. O’Connor, Ellis Levine, Paweł Kaliński	1
3	Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters 2023 ·The Oncologist ·Ahmad Shariftabrizi, Shalin Kothari, Saby George, Kristopher Attwood, Ellis Levine, Dominick Lamonica	2
4	Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study 2023 ·The Breast ·(unknown), Carlos H. Bárcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis Levine, Nancy U. Lin, Beverly Moy, Joyce C. Niland, Antonio C. Wolff, Michael J. Hassett, (unknown), Daniel G. Stover	0
5	Pembrolizumab (Pem) in metastatic castration-resistant prostate cancer (mCRPC): Experience from a comprehensive cancer center. 2023 ·Journal of Clinical Oncology ·Arya Mariam Roy, (unknown), (unknown), (unknown), Ellis Levine, Gurkamal Chatta, Dharmesh Gopalakrishnan	0
6	Determinants of response to CDK4/6 inhibitors in the real-world setting 2023 ·npj Precision Oncology ·Agnieszka K. Witkiewicz, Emily Schultz, Jianxin Wang, (unknown), Ellis Levine, Tracey L. O’Connor, Erik S. Knudsen	16
7	Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx 2023 ·Journal for ImmunoTherapy of Cancer ·Shipra Gandhi, Mateusz Opyrchal, Melissa Grimm, (unknown), Kathleen M. Kokolus, Agnieszka K. Witkiewicz, Kristopher Attwood, Adrienne Groman, Lauren Williams, (unknown), Paul K. Wallace, (unknown), Hans Minderman, Orla Maguire, Tracey L. O’Connor, Amy Early, Ellis Levine, Paweł Kaliński	10
8	Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216) 2022 ·Journal of Clinical Oncology ·Neeraj Agarwal, Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Melissa Plets, Primo N. Lara, Andrea Harzstark, Przemyslaw Twardowski, Channing J. Paller, Dylan M. Zylla, Matthew R. Zibelman, Ellis Levine, Bruce J. Roth, Amir Goldkorn, Daniel A. Vaena, Manish Kohli, Tony Crispino, Nicholas J. Vogelzang, Ian M. Thompson, David I. Quinn	30
9	Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center 2022 ·The Oncologist ·Erik S. Knudsen, Emily Schultz, (unknown), Kristopher Attwood, Stephen B. Edge, Tracey L. O’Connor, Ellis Levine, Agnieszka K. Witkiewicz	20
10	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group 2021 ·Journal of Clinical Oncology ·Roisín M. Connolly, Fengmin Zhao, Kathy D. Miller, Min-Jung Lee, Richard Piekarz, Karen L. Smith, Ursa Brown‐Glaberman, (unknown), Bryan A. Faller, Adedayo A. Onitilo, Mark E. Burkard, G. Thomas Budd, Ellis Levine, Melanie Royce, Peter A. Kaufman, Alexandra Thomas, Jane B. Trepel, Antonio C. Wolff, Joseph A. Sparano	76
11	Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib 2020 ·Breast Cancer Basic and Clinical Research ·(unknown), Roby Thomas, Ellis Levine, Adam Brufsky, Kazuaki Takabe, Matthew G. Hanna, Kristopher Attwood, Austin Miller, Thaer Khoury, Amy Early, (unknown), Tracy O’Connor, Mateusz Opyrchal	27
12	Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma 2015 ·Clinical Genitourinary Cancer ·Venkata K. Pokuri, (unknown), Zhengyu Yang, (unknown), (unknown), Роберто Пили, Ellis Levine, Gissou Azabdaftari, Donald L. Trump, Khurshid A. Guru, Saby George	46
13	Time-trends in survival in young women with breast cancer in a SEER population-based study 2013 ·Breast Cancer Research and Treatment ·Foluso O. Ademuyiwa, Adrienne Groman, Chi-Chen Hong, Austin Miller, Shicha Kumar, Ellis Levine, Deborah O. Erwin, Christine B. Ambrosone	27
14	Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis 2011 ·Medical Oncology ·Nuttapong Ngamphaiboon, Tracey L. O’Connor, Pooja Advani, Ellis Levine, (unknown)	17
15	Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (Calcitriol) in combination with dexamethasone for castration‐resistant prostate cancer 2010 ·Cancer ·Manpreet Chadha, Lili Tian, Terry Mashtare, (unknown), (unknown), Ellis Levine, Michael K. Wong, Candace S. Johnson, Donald L. Trump	42
16	Phase II study of fulvestrant (faslodex®) in castration resistant prostate cancer 2008 ·The Prostate ·Manpreet Chadha, (unknown), David Lawrence, Lili Tian, Ellis Levine, (unknown), (unknown), (unknown), Donald L. Trump	21
17	Is MUGA Scan Necessary in Patients With Low-Risk Breast Cancer Before Doxorubicin-Based Adjuvant Therapy? 2001 ·American Journal of Clinical Oncology ·Michael S. Sabel, Ellis Levine, Thelma C. Hurd, Gary N. Schwartz, Robert Zielinski, D. Höhn, Stephen B. Edge	28
18	Treatment of refractory testis cancer: Salvage or savage chemotherapy? 1991 ·European Journal of Cancer and Clinical Oncology ·Ellis Levine, Derek Raghavan	2
19	Cytogenetics of non-Hodgkin's lymphoma. 1990 ·PubMed ·Ellis Levine, Clara D. Bloomfield	19
20	Autologous bone marrow transplantation in non-Hodgkin's lymphoma: monoclonal antibodies plus complement for ex Vivo marrow treatment 1988 ·The American Journal of Medicine ·David D. Hurd, Tucker W. LeBien, Larry C. Lasky, Robert J. Haake, Norma K.C. Ramsay, Tae Hyong Kim, Ellis Levine, Philip B. McGlave, Clara D. Bloomfield, B. A. Peterson, John H. Kersey	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact